A Precision Exit

Seroba was pleased to see its portfolio company, PrecisionBiotics, acquired by Novozymes in June 2020. The company, originally known as Alimentary Health, was a global pioneer in the study of the human microbiome and of the application of that knowledge to improvements in human health.

Partnering with the world-leading APC Microbiome Centre in Cork, Ireland, the company went on to develop precision biotics, or focused probiotics, that treat specific indications.  For instance, the well-known brand Alflorex® which has been voted 'top product' several years in a row in the Irish Pharmacy Awards, was developed by PrecisionBiotics specifically to treat IBS (Irritable Bowel Syndrome). Another of the company's products, Zenflore®, takes advantage of the gut-brain axis to provide stress-reducing benefits.

Precision Biotics Science Pic

Details of the Deal

Novozymes acquired 100% of the equity of Precisions Biotics Group (PB) for an upfront amount of €80,000,000 on a cash and debt-free basis. In addition to the upfront payment, there will be an additional performance-based earn-out. Seroba was the only institutional investor in the company.

The acquisition of PrecisionBiotics is expected to give Novozymes a stronger entry point into the €5Bn global human probiotic supplements market. Read more.

We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top